Ziyaad Valley-Omar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ziyaad Valley-Omar has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
Arash Iranzadeh
Division of Medical Virology, University of Cape Town, Cape Town, Western Cape, South Africa; National Health Laboratory Service, South Africa
4 shared publicationsDeelan Doolabh
Division of Medical Virology, University of Cape Town, Cape Town, Western Cape, South Africa; National Health Laboratory Service, South Africa
4 shared publications- Diana Ruth Hardie
University of Cape Town
4 shared publications - Nei-Yuan Hsiao
University of Cape Town
4 shared publications Andrew Boulle
Health Intelligence, Western Cape Government: Health, South Africa; Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, South Africa
3 shared publicationsCarolyn Williamson
Division of Medical Virology, University of Cape Town, Cape Town, Western Cape, South Africa; National Health Laboratory Service, South Africa; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by AOSIS in Journal of the Colleges of Medicine of South Africa
- Vol. 4 (1) , 13
The molecular epidemiology of human respiratory syncytial virus in a tertiary paediatric hospital between 2020 and 2024
Background: Respiratory syncytial virus (RSV) is a leading cause of respiratory illness in young children, contributing significantly to morbidity and mortality and placing a substantial burden on resource-limited healthcare systems. Molecular epidemiological data from sub-Saharan Africa remain limited. This study aimed to investigate the genetic diversity and evolution of RSV in a paediatric population in Cape Town, South Africa, from September 2020 to June 2024. Methods: Respiratory syncytial virus-positive respiratory samples with a cycle threshold (Ct) < 30 from patients at Red Cross War Memorial Children’s Hospital were sequenced and analysed. Phylogenetic analysis of the partial RSV genome (F and G genes) was conducted using reference sequences derived from a global sequence database. Mutational profiles were assessed for relevance to monoclonal antibody and vaccine effectiveness. Results: Of the 100 selected samples, 42 were sequenced, and 40 had sufficient coverage for analysis. Sequencing failure was associated with higher Ct values, older sample age and suboptimal storage at −20°C. Respiratory syncytial virus-A predominated (78.6%), with A.D.5.1 as the dominant lineage; RSV-B strains (16.7%) clustered within B.D.E.1 and B.D.4.1. Genotypes GA2.3.5 (RSV-A) and GB5.0.5a (RSV-B) were observed, consistent with post-pandemic global trends. G-gene analysis revealed multiple substitutions (G224E, I134K, K262E) suggestive of immune pressure. The F-gene remained more conserved; substitutions such as T122A, S211N and S389P were detected but were not linked to reduced susceptibility to monoclonals. Conclusion: This study demonstrated the co-circulation of genetically diverse RSV-A and RSV-B lineages in children between 2020 and 2024. No established resistance-associated substitutions to currently licensed RSV monoclonal antibodies were identified. Continued genomic surveillance is warranted to monitor RSV evolution. Contribution: Continued genomic surveillance is essential to strengthen molecular epidemiology and guide public health preparedness.
- 1 January 2026
- Published by AOSIS in Journal of the Colleges of Medicine of South Africa
- Vol. 4 (1) , 13
Open AccessThe molecular epidemiology of human respiratory syncytial virus in a tertiary paediatric hospital between 2020 and 2024
Background: Respiratory syncytial virus (RSV) is a leading cause of respiratory illness in young children, contributing significantly to morbidity and mortality and placing a substantial burden on resource-limited healthcare systems. Molecular epidemiological data from sub-Saharan Africa remain limited. This study aimed to investigate the genetic diversity and evolution of RSV in a paediatric population in Cape Town, South Africa, from September 2020 to June 2024. Methods: Respiratory syncytial virus-positive respiratory samples with a cycle threshold (Ct) < 30 from patients at Red Cross War Memorial Children’s Hospital were sequenced and analysed. Phylogenetic analysis of the partial RSV genome (F and G genes) was conducted using reference sequences derived from a global sequence database. Mutational profiles were assessed for relevance to monoclonal antibody and vaccine effectiveness. Results: Of the 100 selected samples, 42 were sequenced, and 40 had sufficient coverage for analysis. Sequencing failure was associated with higher Ct values, older sample age and suboptimal storage at −20°C. Respiratory syncytial virus-A predominated (78.6%), with A.D.5.1 as the dominant lineage; RSV-B strains (16.7%) clustered within B.D.E.1 and B.D.4.1. Genotypes GA2.3.5 (RSV-A) and GB5.0.5a (RSV-B) were observed, consistent with post-pandemic global trends. G-gene analysis revealed multiple substitutions (G224E, I134K, K262E) suggestive of immune pressure. The F-gene remained more conserved; substitutions such as T122A, S211N and S389P were detected but were not linked to reduced susceptibility to monoclonals. Conclusion: This study demonstrated the co-circulation of genetically diverse RSV-A and RSV-B lineages in children between 2020 and 2024. No established resistance-associated substitutions to currently licensed RSV monoclonal antibodies were identified. Continued genomic surveillance is warranted to monitor RSV evolution. Contribution: Continued genomic surveillance is essential to strengthen molecular epidemiology and guide public health preparedness.
- Open Access
- 13 October 2025
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 32 (11) , e70095
Performance Evaluation of the Elecsys HCV Duo Immunoassay in the Public Healthcare Setting in Cape Town, South Africa
Improved HCV diagnosis and linkage to care is crucial to achieve WHO 2030 elimination targets. Simplification of diagnostics remains key. We evaluated the performance of Elecsys HCV Duo antigen/antibody immunoassay in patients using public healthcare in Cape Town, South Africa. 253 HCV seropositive and 214 seronegative samples were tested, and results correlated with standard‐of‐care (SOC) serology, HCV RNA, viral genotype, patient demographics, and disease markers. Thirteen patients on antiviral therapy were also evaluated. Elecsys HCV Duo antibody was equivalent to SOC serology, while antigen had 100% negative percent agreement in non‐viraemic samples. One incident infection with viral load (VL) of 54,000 IU/mL was antigen positive/antibody negative. Overall, antigen detection was 63.2% in RNA‐positive samples. VL strongly predicted reactivity, with antigen positive rates of 17.5% (< 5 log IU/mL), 75.8% (5–6 log IU/mL), 89.4% (6–7 log IU/mL), and 100% (> 7 log IU/mL). Detection in genotype‐1 infections was significantly better, at 69.6% (95% CI 59.5–79.7) than non‐genotype‐1 at 43.2% (95% CI 28.7–57.7). In treated patients, antigen mirrored RNA clearance but was only reliable if positive at baseline. Elecsys HCV Duo detected active infection in 63% of viraemic patients, 70% with genotype 1. In our cohort, 49% of new patients would require VL testing.
- 13 October 2025
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 32 (11) , e70095
Open AccessPerformance Evaluation of the Elecsys HCV Duo Immunoassay in the Public Healthcare Setting in Cape Town, South Africa
Improved HCV diagnosis and linkage to care is crucial to achieve WHO 2030 elimination targets. Simplification of diagnostics remains key. We evaluated the performance of Elecsys HCV Duo antigen/antibody immunoassay in patients using public healthcare in Cape Town, South Africa. 253 HCV seropositive and 214 seronegative samples were tested, and results correlated with standard‐of‐care (SOC) serology, HCV RNA, viral genotype, patient demographics, and disease markers. Thirteen patients on antiviral therapy were also evaluated. Elecsys HCV Duo antibody was equivalent to SOC serology, while antigen had 100% negative percent agreement in non‐viraemic samples. One incident infection with viral load (VL) of 54,000 IU/mL was antigen positive/antibody negative. Overall, antigen detection was 63.2% in RNA‐positive samples. VL strongly predicted reactivity, with antigen positive rates of 17.5% (< 5 log IU/mL), 75.8% (5–6 log IU/mL), 89.4% (6–7 log IU/mL), and 100% (> 7 log IU/mL). Detection in genotype‐1 infections was significantly better, at 69.6% (95% CI 59.5–79.7) than non‐genotype‐1 at 43.2% (95% CI 28.7–57.7). In treated patients, antigen mirrored RNA clearance but was only reliable if positive at baseline. Elecsys HCV Duo detected active infection in 63% of viraemic patients, 70% with genotype 1. In our cohort, 49% of new patients would require VL testing.
- Open Access
Performance Evaluation of the Elecsys HCV Duo Immunoassay in the Public Healthcare setting in Cape Town, South Africa
Objectives: Improved hepatitis C virus (HCV) diagnosis and linkage to care is crucial to achieve WHO 2030 elimination targets. Simplification of diagnostics remains key. We evaluated the performance of Elecsys HCV Duo antigen/antibody immunoassay in patients using public healthcare in Cape Town, South Africa. Methods: 253 HCV seropositive and 214 seronegative samples were tested, and results correlated with standard-of-care (SOC) serology, RNA, viral genotype, patient demographics and disease markers. Thirteen patients on antiviral-therapy were also evaluated. Results: Elecsys HCV Duo antibody was equivalent to SOC serology, while antigen had 100% negative percent agreement in non-viraemic samples. One incident infection with viral load of 54000 IU/mL was antigen positive/antibody negative. Overall, antigen detection was 62.2% in RNA-positive samples. Viral load strongly predicted reactivity, with antigen positive rates of 17.5% (7 log IU/mL). Antigen detection in genotype-1 infections was significantly better at 69.6% (95% CI 59.5-79.7) than for non-genotype-1 at 43.2% (95% CI 28.7-57.7). In treated patients, antigen mirrored RNA clearance but was only reliable if positive at baseline. Conclusion: Elecsys HCV Duo detected active infection in 62% of viraemic patients and in 70% with genotype-1. In our cohort, 49% of newly diagnosed patients would require RNA testing. Highlights: Elecsys HCV Duo detected active infection in 63% of new HCV RNA positive patients Genotype-1 status and RNA >6 log IU/mL are determinants of antigen positivity In antiviral therapy, antigen mirrors RNA decay, and is useful if baseline positive 49% of new HCV patients would still require RNA test to determine viraemia
Open AccessPerformance Evaluation of the Elecsys HCV Duo Immunoassay in the Public Healthcare setting in Cape Town, South Africa
Objectives: Improved hepatitis C virus (HCV) diagnosis and linkage to care is crucial to achieve WHO 2030 elimination targets. Simplification of diagnostics remains key. We evaluated the performance of Elecsys HCV Duo antigen/antibody immunoassay in patients using public healthcare in Cape Town, South Africa. Methods: 253 HCV seropositive and 214 seronegative samples were tested, and results correlated with standard-of-care (SOC) serology, RNA, viral genotype, patient demographics and disease markers. Thirteen patients on antiviral-therapy were also evaluated. Results: Elecsys HCV Duo antibody was equivalent to SOC serology, while antigen had 100% negative percent agreement in non-viraemic samples. One incident infection with viral load of 54000 IU/mL was antigen positive/antibody negative. Overall, antigen detection was 62.2% in RNA-positive samples. Viral load strongly predicted reactivity, with antigen positive rates of 17.5% (7 log IU/mL). Antigen detection in genotype-1 infections was significantly better at 69.6% (95% CI 59.5-79.7) than for non-genotype-1 at 43.2% (95% CI 28.7-57.7). In treated patients, antigen mirrored RNA clearance but was only reliable if positive at baseline. Conclusion: Elecsys HCV Duo detected active infection in 62% of viraemic patients and in 70% with genotype-1. In our cohort, 49% of newly diagnosed patients would require RNA testing. Highlights: Elecsys HCV Duo detected active infection in 63% of new HCV RNA positive patients Genotype-1 status and RNA >6 log IU/mL are determinants of antigen positivity In antiviral therapy, antigen mirrors RNA decay, and is useful if baseline positive 49% of new HCV patients would still require RNA test to determine viraemia
- Open Access
- 27 May 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (6) , 575
Human Leukocyte Antigen-Allelic Variations May Influence the Age at Cancer Diagnosis in Lynch Syndrome
Lynch syndrome (LS) is an inherited cancer predisposition disorder associated with an elevated risk of developing various solid cancers, but mostly colorectal cancer (CRC). Despite having the same germline pathogenic variant (PV) in one of the mis-match repair genes or the EPCAM gene, Lynch syndrome variant heterozygotes (LSVH) exhibit a remarkable phenotypic variability in the risk of developing cancer. The role of human leukocyte antigen (HLA) in modifying cancer development risk prompted our hypothesis into whether HLA variations act as potential genetic modifiers influencing the age at cancer diagnosis in LSVH. To investigate this, we studied a unique cohort of 426 LSVH carrying the same germline PV in the hMLH1 gene (MLH1:c.1528C > T) in South Africa. We intuitively selected 100 LSVH with the greatest diversity in age at cancer diagnosis (N = 80) and the oldest cancer unaffected LSVH (N = 20) for a high-throughput HLA genotyping of 11 HLA class I and class II loci using the shotgun next-generation sequencing (NGS) technique on the Illumina MiSeq platform. Statistical analyses employed Kaplan–Meier survival analyses with log-rank tests, and Cox proportional hazards using binned HLA data to minimize type I error. Significant associations were observed between young age at cancer diagnosis and HLA-DPB1*04:02 (mean age: 37 y (25–50); hazard ratio (HR) = 3.37; corrected p-value (q) = 0.043) as well as HLA-DPB1 binned alleles (including HLA-DPB1*09:01, HLA-DPB1*10:01, HLA-DPB1*106:01, HLA-DPB1*18:01, HLA-DPB1*20:01, HLA-DPB1*26:01, HLA-DPB1*28:01, HLA-DPB1*296:01, and HLA-DPB1*55:01) (mean age: 37 y (17–63); HR = 2.30, q = 0.045). The involvement of HLA-DPB1 alleles in the age at cancer diagnosis may highlight the potential role of HLA class II in the immune response against cancer development in LSVH. When validated in a larger cohort, these high-risk HLA-DPB1 alleles could be factored into cancer risk prediction models for personalized cancer screening in LSVH.
- 27 May 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (6) , 575
Open AccessHuman Leukocyte Antigen-Allelic Variations May Influence the Age at Cancer Diagnosis in Lynch Syndrome
Lynch syndrome (LS) is an inherited cancer predisposition disorder associated with an elevated risk of developing various solid cancers, but mostly colorectal cancer (CRC). Despite having the same germline pathogenic variant (PV) in one of the mis-match repair genes or the EPCAM gene, Lynch syndrome variant heterozygotes (LSVH) exhibit a remarkable phenotypic variability in the risk of developing cancer. The role of human leukocyte antigen (HLA) in modifying cancer development risk prompted our hypothesis into whether HLA variations act as potential genetic modifiers influencing the age at cancer diagnosis in LSVH. To investigate this, we studied a unique cohort of 426 LSVH carrying the same germline PV in the hMLH1 gene (MLH1:c.1528C > T) in South Africa. We intuitively selected 100 LSVH with the greatest diversity in age at cancer diagnosis (N = 80) and the oldest cancer unaffected LSVH (N = 20) for a high-throughput HLA genotyping of 11 HLA class I and class II loci using the shotgun next-generation sequencing (NGS) technique on the Illumina MiSeq platform. Statistical analyses employed Kaplan–Meier survival analyses with log-rank tests, and Cox proportional hazards using binned HLA data to minimize type I error. Significant associations were observed between young age at cancer diagnosis and HLA-DPB1*04:02 (mean age: 37 y (25–50); hazard ratio (HR) = 3.37; corrected p-value (q) = 0.043) as well as HLA-DPB1 binned alleles (including HLA-DPB1*09:01, HLA-DPB1*10:01, HLA-DPB1*106:01, HLA-DPB1*18:01, HLA-DPB1*20:01, HLA-DPB1*26:01, HLA-DPB1*28:01, HLA-DPB1*296:01, and HLA-DPB1*55:01) (mean age: 37 y (17–63); HR = 2.30, q = 0.045). The involvement of HLA-DPB1 alleles in the age at cancer diagnosis may highlight the potential role of HLA class II in the immune response against cancer development in LSVH. When validated in a larger cohort, these high-risk HLA-DPB1 alleles could be factored into cancer risk prediction models for personalized cancer screening in LSVH.
- Open Access
- 7 March 2024
- Published by MDPI AG in Preprints.org
Human Leukocyte Antigen-Allelic Variations May Influence the Age at Cancer Diagnosis in Lynch Syndrome
Lynch syndrome (LS) is an inherited cancer predisposition disorder associated with an elevated risk of various epithelial cancers. Despite sharing the same pathogenic variant (PV), Lynch syn-drome variant heterozygotes (LSVH) exhibit considerable phenotypic variability in cancer risk. The role of Human Leukocyte Antigen (HLA) in modifying cancer risk prompted our investiga-tion into whether HLA variations act as genetic modifiers influencing age at cancer diagnosis in a unique cohort of LSVH carrying a PV in the hMLH1 gene in South Africa. Within our extensive LS cohort, 426 individuals carried the same hMLH1 PV (MLH1:c.1528C>T). We selected 100 indi-viduals with the greatest diversity in age at cancer diagnosis and the oldest unaffected individu-als for high-throughput HLA genotyping of 12 HLA class I and II loci using next-generation se-quencing. Statistical analyses employed Kaplan-Meier survival analyses with Logrank tests and Cox proportional hazards. Following the robust application of statistical correction methods, six HLA alleles (3.2%) were significantly associated with a young age at cancer diagnosis. Notably, HLA-B*15:17 and HLA-DPB1*55:01 correlated significantly with very young colorectal cancer (CRC) diagnosis (Mean age: 21y [17-25]; HR = 71.59; q
- 7 March 2024
- Published by MDPI AG in Preprints.org
Open AccessHuman Leukocyte Antigen-Allelic Variations May Influence the Age at Cancer Diagnosis in Lynch Syndrome
Lynch syndrome (LS) is an inherited cancer predisposition disorder associated with an elevated risk of various epithelial cancers. Despite sharing the same pathogenic variant (PV), Lynch syn-drome variant heterozygotes (LSVH) exhibit considerable phenotypic variability in cancer risk. The role of Human Leukocyte Antigen (HLA) in modifying cancer risk prompted our investiga-tion into whether HLA variations act as genetic modifiers influencing age at cancer diagnosis in a unique cohort of LSVH carrying a PV in the hMLH1 gene in South Africa. Within our extensive LS cohort, 426 individuals carried the same hMLH1 PV (MLH1:c.1528C>T). We selected 100 indi-viduals with the greatest diversity in age at cancer diagnosis and the oldest unaffected individu-als for high-throughput HLA genotyping of 12 HLA class I and II loci using next-generation se-quencing. Statistical analyses employed Kaplan-Meier survival analyses with Logrank tests and Cox proportional hazards. Following the robust application of statistical correction methods, six HLA alleles (3.2%) were significantly associated with a young age at cancer diagnosis. Notably, HLA-B*15:17 and HLA-DPB1*55:01 correlated significantly with very young colorectal cancer (CRC) diagnosis (Mean age: 21y [17-25]; HR = 71.59; q
- Open Access
- 2 August 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (15) , 2576
Human Parainfluenza Virus (HPIV) Detection in Hospitalized Children with Acute Respiratory Tract Infection in the Western Cape, South Africa during 2014–2022 Reveals a Shift in Dominance of HPIV 3 and 4 Infections
The epidemiology of human parainfluenza viruses (HPIV), particularly its role as a cause of acute respiratory infection (ARI) in infants, has not been formally studied in South Africa. We evaluated HPIV prevalence in diagnostic samples from hospitalized children from public sector hospitals in the Western Cape between 2014 and 2022. HPIV infection was detected in 2–10% of patients, with the majority of infections detected in children less than 1 year of age. Prior to 2020, HPIV 4 (40%) and HPIV 3 (34%) were the most prevalent types, with seasonal peaks in late winter/spring for HPIV 3 and autumn/winter for HPIV 4. HPIV 4A and 4B co-circulated during the seasonal activity between 2014 and 2017. Pandemic restrictions in 2020 had a profound effect on HPIV circulation and the rebound was dominated by waves of HPIV 3, accounting for 66% of detections and a sustained decline in the circulation of HPIV 1, 2 and 4. An immunity gap could account for the surge in HPIV 3 infections, but the decline in prior HPIV 4 dominance is unexplained and requires further study.
- 2 August 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (15) , 2576
Open AccessHuman Parainfluenza Virus (HPIV) Detection in Hospitalized Children with Acute Respiratory Tract Infection in the Western Cape, South Africa during 2014–2022 Reveals a Shift in Dominance of HPIV 3 and 4 Infections
The epidemiology of human parainfluenza viruses (HPIV), particularly its role as a cause of acute respiratory infection (ARI) in infants, has not been formally studied in South Africa. We evaluated HPIV prevalence in diagnostic samples from hospitalized children from public sector hospitals in the Western Cape between 2014 and 2022. HPIV infection was detected in 2–10% of patients, with the majority of infections detected in children less than 1 year of age. Prior to 2020, HPIV 4 (40%) and HPIV 3 (34%) were the most prevalent types, with seasonal peaks in late winter/spring for HPIV 3 and autumn/winter for HPIV 4. HPIV 4A and 4B co-circulated during the seasonal activity between 2014 and 2017. Pandemic restrictions in 2020 had a profound effect on HPIV circulation and the rebound was dominated by waves of HPIV 3, accounting for 66% of detections and a sustained decline in the circulation of HPIV 1, 2 and 4. An immunity gap could account for the surge in HPIV 3 infections, but the decline in prior HPIV 4 dominance is unexplained and requires further study.
- Open Access
- 27 February 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 118, 150-154
Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections – a survival analysis
- 27 February 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 118, 150-154
Open AccessAssessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections – a survival analysis
- Open Access
- 9 February 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (631) , eabj6824
Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity
SARS-CoV-2 variants that escape neutralization and potentially affect vaccine efficacy have emerged. T cell responses play a role in protection from reinfection and severe disease, but the potential for spike mutations to affect T cell immunity is incompletely understood. We assessed neutralizing antibody and T cell responses in 44 South African COVID-19 patients either infected with the Beta variant (dominant from November 2020 to May 2021) or infected before its emergence (first wave, Wuhan strain) to provide an overall measure of immune evasion. We show that robust spike-specific CD4 and CD8 T cell responses were detectable in Beta-infected patients, similar to first-wave patients. Using peptides spanning the Beta-mutated regions, we identified CD4 T cell responses targeting the wild-type peptides in 12 of 22 first-wave patients, all of whom failed to recognize corresponding Beta-mutated peptides. However, responses to mutated regions formed only a small proportion (15.7%) of the overall CD4 response, and few patients (3 of 44) mounted CD8 responses that targeted the mutated regions. Among the spike epitopes tested, we identified three epitopes containing the D215, L18, or D80 residues that were specifically recognized by CD4 T cells, and their mutated versions were associated with a loss of response. This study shows that despite loss of recognition of immunogenic CD4 epitopes, CD4 and CD8 T cell responses to Beta are preserved overall. These observations may explain why several vaccines have retained the ability to protect against severe COVID-19 even with substantial loss of neutralizing antibody activity against Beta.
- 9 February 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (631) , eabj6824
Open AccessEscape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity
SARS-CoV-2 variants that escape neutralization and potentially affect vaccine efficacy have emerged. T cell responses play a role in protection from reinfection and severe disease, but the potential for spike mutations to affect T cell immunity is incompletely understood. We assessed neutralizing antibody and T cell responses in 44 South African COVID-19 patients either infected with the Beta variant (dominant from November 2020 to May 2021) or infected before its emergence (first wave, Wuhan strain) to provide an overall measure of immune evasion. We show that robust spike-specific CD4 and CD8 T cell responses were detectable in Beta-infected patients, similar to first-wave patients. Using peptides spanning the Beta-mutated regions, we identified CD4 T cell responses targeting the wild-type peptides in 12 of 22 first-wave patients, all of whom failed to recognize corresponding Beta-mutated peptides. However, responses to mutated regions formed only a small proportion (15.7%) of the overall CD4 response, and few patients (3 of 44) mounted CD8 responses that targeted the mutated regions. Among the spike epitopes tested, we identified three epitopes containing the D215, L18, or D80 residues that were specifically recognized by CD4 T cells, and their mutated versions were associated with a loss of response. This study shows that despite loss of recognition of immunogenic CD4 epitopes, CD4 and CD8 T cell responses to Beta are preserved overall. These observations may explain why several vaccines have retained the ability to protect against severe COVID-19 even with substantial loss of neutralizing antibody activity against Beta.
- Open Access
- 18 January 2022
- Published by Elsevier in Journal of Virological Methods
- Vol. 302, 114471
Reduced amplification efficiency of the RNA-dependent-RNA-polymerase target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests
- 18 January 2022
- Published by Elsevier in Journal of Virological Methods
- Vol. 302, 114471
Open AccessReduced amplification efficiency of the RNA-dependent-RNA-polymerase target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests
- Open Access
Reduced amplification efficiency of the RNA-dependent-RNA-polymerase (RdRp) target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests
Routine SARS-CoV-2 surveillance in the Western Cape region of South Africa (January-August 2021) found a reduced PCR amplification efficiency of the RdRp gene target of the Seegene, Allplex 2019-nCoV diagnostic assay when detecting the Delta variant. We propose that this can be used as a surrogate for variant detection.
Open AccessReduced amplification efficiency of the RNA-dependent-RNA-polymerase (RdRp) target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests
Routine SARS-CoV-2 surveillance in the Western Cape region of South Africa (January-August 2021) found a reduced PCR amplification efficiency of the RdRp gene target of the Seegene, Allplex 2019-nCoV diagnostic assay when detecting the Delta variant. We propose that this can be used as a surrogate for variant detection.